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LEADING ARTICLE
Overview of Current Drugs and Molecules in Development
for Spinal Muscular Atrophy Therapy
Hannah K. Shorrock1,2 • Thomas H. Gillingwater1,2 • Ewout J. N. Groen1,2
 The Author(s) 2018. This article is an open access publication
Abstract Spinal muscular atrophy (SMA) is a neurode-
generative disease primarily characterized by a loss of
spinal motor neurons, leading to progressive paralysis and
premature death in the most severe cases. SMA is caused
by homozygous deletion of the survival motor neuron 1
(SMN1) gene, leading to low levels of SMN protein.
However, a second SMN gene (SMN2) exists, which can be
therapeutically targeted to increase SMN levels. This has
recently led to the first disease-modifying therapy for SMA
gaining formal approval from the US Food and Drug
Administration (FDA) and European Medicines Agency
(EMA). Spinraza (nusinersen) is a modified antisense
oligonucleotide that targets the splicing of SMN2, leading
to increased SMN protein levels, capable of improving
clinical phenotypes in many patients. In addition to Spin-
raza, several other therapeutic approaches are currently in
various stages of clinical development. These include
SMN-dependent small molecule and gene therapy
approaches along with SMN-independent strategies, such
as general neuroprotective factors and muscle strength-
enhancing compounds. For each therapy, we provide
detailed information on clinical trial design and pharma-
cological/safety data where available. Previous clinical
studies are also discussed to provide context on SMA
clinical trial development and the insights these provided
for the design of current studies.
Key Points
The approval of Spinraza for the treatment of spinal
muscular atrophy is a major milestone in motor
neuron disease and translational research.
Numerous additional therapies, both survival motor
neuron (SMN)-dependent and SMN-independent, are
currently in development and will likely expand
therapeutic possibilities in coming years.
Future research will have a strong focus on
identifying combinatorial therapeutic strategies by
combining SMN-targeting therapy with other, SMN-
independent therapies.
1 Introduction
Spinal muscular atrophy (SMA) is a devastating neuro-
logical disease characterized primarily by the degeneration
of lower motor neurons in the spinal cord [1]. SMA is the
most common genetic cause of infant mortality and occurs
in approximately one in 10,000 live births [2]. The
monogenetic cause of SMA has long been known [3],
which has allowed basic research on SMA to always have a
strong focus on therapy development. These research
efforts have led to the development and recent approval of
the first disease-modifying therapy for SMA, Spinraza
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(nusinersen), an important milestone in SMA and neuro-
muscular disease research [4–6]. Initial experiences with
Spinraza have already provided important lessons for the
development of therapies for related motor neuron diseases
and other monogenetic neurological disorders. Several
additional therapies for SMA are now in various stages of
clinical development, and basic research has identified
further promising preclinical leads. In this review, we first
provide an overview of the clinical, genetic and pathogenic
background of SMA. Next, we detail current clinical
studies, including pharmacological and safety data where
available. Finally, we discuss future directions and priori-
ties for SMA therapy development.
2 Clinical, Genetic and Pathogenic Background
of Spinal Muscular Atrophy (SMA)
2.1 Clinical Background of SMA
Despite its established monogenetic cause, the clinical
phenotype of SMA is highly variable [1, 7]. SMA patients
with the most severe (type 0, neonatal onset) and common
(type I, approximately 50% of all cases) forms are char-
acterized by disease onset before 6 months of age. These
patients do not reach any major motor milestones and die
before the age of 2 years. SMA type II patients present at a
later age (between 6 and 18 months), usually learn to sit
unaided, but are never able to stand or walk and have a
severely reduced life expectancy. SMA type III is clinically
very heterogeneous, ranging from patients with severe
neuromuscular disability to patients who are relatively
mildly affected. Both age of onset and life expectancy are
equally variable in these forms of the disease. Finally,
SMA type IV is the mildest form of SMA, with disease
onset not normally occurring before the third decade,
comparatively minor disability and normal life expectancy.
Based on underlying genetics, motor milestones and clin-
ical phenotype, further subdivisions into clinical subtypes
(type Ia, Ib and Ic and type IIa, IIb, IIIa and IIIb) can be
made [8].
2.2 Genetics of SMA
SMA is caused by a homozygous deletion of the survival
motor neuron 1 (SMN1) gene in * 95% of cases and other
deleterious variants in SMN1 in the remaining * 5% of
cases [3]. These variants unanimously lead to low levels of
functional SMN protein [9]. Humans have a second copy of
this gene, known as SMN2, which is almost identical to
SMN1. However, in SMN2, a synonymous nucleotide
substitution at the 50 end of exon 7 leads to exon skipping
and translation into unstable, quickly degraded truncated
SMN protein (SMND7) for the majority of transcripts
[10, 11]. The number of SMN2 copies is variable, and
because each copy produces low levels of full-length,
functional SMN, the number of SMN2 copies correlates
well with a patient’s clinical phenotype [12]. However,
both between patients with the same number of SMN2
copies and within families, considerable variation in clin-
ical phenotypes can occur. Indeed, research on discordant
families has led to the identification of several genetic
modifiers of SMA, including plastin-3 (PLS3) and neuro-
calcin delta (NCALD) (see also Sect. 4.1) [13–15]. It is
likely, therefore, that further genetic and other disease-
modifying factors are still to be discovered.
2.3 Cellular Mechanisms of SMA
Because of its central role in the pathogenesis of SMA,
SMN’s cellular role has been extensively studied. SMN is a
ubiquitously expressed, 32-kDa protein. SMN has an
important housekeeping role in all cells with regard to
regulating the biogenesis of ribonucleoprotein (RNP)
complexes, of which its role in the formation of small
nuclear RNPs (snRNPs) has been studied in most detail
[16–21]. By interacting with GEMIN2–8 and unrip, SMN
regulates the binding of small nuclear ribonucleic acids
(snRNAs) to Sm proteins and subsequently guides these
RNA–protein complexes from the cytoplasm into the
nucleus. There, the newly formed snRNPs mature in
nuclear Cajal bodies, after which they move into nuclear
speckles to be recruited into active spliceosomes. Recent
research indicates that SMN has in fact a general role in
RNP formation, as illustrated by defects in the formation of
small nucleolar RNPs (snoRNPs) (required for the post-
translational modification of non-coding RNAs), messen-
ger RNPs (mRNPs) (involved in the transport of mRNAs),
and signal recognition particles (SRPs) (regulating the
transport of newly synthetized proteins) when SMN levels
are low [19, 22, 23].
SMN depletion affects a number of other cellular
pathways that are of particular interest for the maintenance
of neuronal homeostasis. For example, actin dynamics,
ubiquitin homeostasis, mitochondrial function and endo-
cytosis are all disrupted in SMA [24]. When SMN
expression is reduced to pathological levels, decreased
SMN-profilin interaction leads to increased formation of
profilin–Rho-associated protein kinase (ROCK) complexes
that cause activation of Ras homologue gene family,
member A (RhoA), a negative regulator of axon outgrowth
[25, 26]. Moreover, increased levels of actin-binding pro-
tein PLS3 are protective in both SMA disease models and
patients [13, 14]. Furthermore, decreased levels of the E1
ubiquitin-activating enzyme, ubiquitin-like modifier acti-
vating enzyme 1 (UBA1), are a central feature of SMA
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pathogenesis across a range of models, and therapeutic
targeting of UBA1 rescues a range of SMA-associated
phenotypes [27, 28]. In addition, a number of studies have
indicated defects in mitochondrial function and transport in
SMA, including decreased expression of specific mito-
chondrial proteins such as phosphoglycerate kinase 1
(PGK1) [29, 30]. Finally, the role of NCALD as a genetic
modifier illustrates how, by interacting with actin and
clathrin, endocytotic processes can be affected in SMA and
influence disease phenotypes [15]. Whether the above
pathways are related or whether they are independently
affected in SMA remains to be determined. Interestingly,
however, local protein translation (both globally and at the
level of specific mRNAs) is defective in several SMA
models [31–34]. Careful spatiotemporal regulation of local
protein translation is vital for maintaining neuronal
homeostasis and has been linked to many of the above
pathways [35, 36], thereby providing a possible cellular
pathway that links and unites these molecular mechanisms
in the pathogenesis of SMA.
3 Current SMA Therapy Developments
Because severely reduced levels of SMN have long been
known to be the cause of SMA, therapy development has
so far largely focused on approaches that aim to increase
full-length SMN protein levels [37]. These approaches
include antisense oligonucleotides (ASOs) and small
molecules that target SMN2, and gene therapy to restore
SMN1 and cellular SMN expression. Each of these
approaches has shown great promise in preclinical studies,
often leading to significant amelioration of disease phe-
notypes in a range of animal models [38–42]. The same
preclinical studies, however, have also indicated several
limitations and requirements when treating SMA by tar-
geting SMN. First, the timing of SMN-targeted therapies in
SMA mouse models has been shown to be essential for the
efficient rescue of disease phenotypes; the earlier treatment
is started, the more robustly the disease phenotype is res-
cued [43]. Data emerging from recent clinical trials have
suggested that this is also an important aspect of therapy in
SMA patients. This finding might limit the efficacy of
SMN-targeted therapies, as initial diagnosis of SMA fol-
lowing symptom onset might suggest that the optimal
therapeutic window for therapy delivery has already pas-
sed. Moreover, although lower motor neurons are the pri-
mary pathogenic target in SMA, studies in animal models
indicate that other, non-central nervous system (non-CNS)
tissues are also affected [44–49]. Although not all organs
are affected to the same extent in all animal models of
SMA, preclinical studies have indicated that restoration of
SMN expression is required in all tissues and not just in the
CNS to provide robust rescue of the SMA phenotype [50].
Several studies and case reports in SMA patients indicate
that, indeed, peripheral tissues can be affected in addition
to motor neuron degeneration [45, 51], confirming that
preclinical findings are also relevant for patient studies.
3.1 Survival Motor Neuron (SMN)-Targeted
Therapies
3.1.1 Spinraza
Spinraza (nusinersen, Biogen/Ionis) is a modified 18-mer
ASO that has been approved for treatment of all types of
SMA in Europe, Canada, Japan, Australia and the USA
(Tables 1 and 2) [5, 52]. It works by binding to the ISS-N1
regulatory motif in the intron downstream of exon 7 on
SMN2 pre-mRNA, preventing the binding of factors such
as heterogeneous nuclear ribonucleoprotein A1
(hnRNPA1). This promotes the inclusion of exon 7,
thereby increasing the amount of full-length SMN2 mRNA
and, subsequently, full-length SMN protein [6]. Spinraza is
administered by intrathecal injection at an equivalent dose
of 12 mg (4–5 mL based on age), with three initial loading
doses at intervals of 14 days and a fourth loading dose
30 days later [53]. The loading phase is followed by
maintenance doses once every 4 months [5, 53]. Following
intrathecal injection, Spinraza is distributed from the
cerebrospinal fluid (CSF) throughout the CNS, including
into motor neurons, glia and vascular endothelial cells [53].
Spinraza is cleared from the CSF into systemic circulation
consistent with normal CSF turnover, with the mean time
to maximum plasma concentration ranging from 1.7 to 6 h.
Consistent with this, Spinraza was detected in kidney, liver
and skeletal muscle along with the CNS at autopsy [53].
Spinraza leads to increased levels of SMN protein, as
detected in CSF [54], increased inclusion of SMN exon 7
and, subjectively, increased levels of SMN protein as
determined by immunohistochemistry on spinal cord [53].
Spinraza was still detectable in the CSF 15–168 days after
dosing, with a mean terminal elimination half-life of
135–177 days in the CSF and 63–87 days in the plasma,
indicating prolonged exposure of the CNS and peripheral
tissues to Spinraza [53, 55].
A phase III clinical trial of Spinraza for SMA type I
(ENDEAR) was performed on 121 patients who presented
with SMA before the age of 7 months. ENDEAR was a
multinational, randomized, double-blind, sham-controlled
clinical trial. Following the final analysis of this study, 51%
of Spinraza-treated patients were motor milestone respon-
ders [as assessed by Sect. 2 of the Hammersmith Infant
Neurological Examination (HINE)] compared to 0% of
controls; however, only 8% of Spinraza-treated patients
were able to sit independently. Moreover, there was a
Therapy Development for Spinal Muscular Atrophy
Table 1 Overview of current SMA trials and therapeutic targets
Druga Target Associated trials Stage Sponsors
Spinraza
[53, 54, 56]
SMN2
splicing
NCT01494701, NCT02052791, NCT01703988, NCT01839656,
NCT02462759 (EMBRACE), NCT02386553 (NURTURE),
NCT02193074 (ENDEAR), NCT02292537 (CHERISH),
NCT02594124 (SHINE), NCT02865109 (EAP)
I/II/III/EAP Biogen, Ionis
AVXS-101
[64]
SMN1 gene
replacement
NCT02122952, phase II trial announced (STR1VE) I/II AveXis, Inc.
Branaplam
(LMI070)
SMN2
splicing
NCT02268552 I/II Novartis Pharmaceuticals
RG7916 SMN2
splicing
NCT02633709, NCT02908685 (SUNFISH), NCT02913482
(FIREFISH), NCT03032172 (JEWELFISH)
I/II Hoffmann-La Roche
Valproic acid
[71–76]
HDAC
inhibitor
NCT00374075, NCT00227266 (CARNI-VAL part 1 and 2),
NCT00481013 (VALIANT), NCT00661453 (CARNI-VAL
Type I)
I/II University of Utah
NCT01033331 – University of Sao Paulo
General Hospital
Olesoxime
[82]
Mitochondria 2006-006845-14, NCT01302600, NCT02628743 I/II Hoffmann-La Roche,
Trophos SA
CK-107 Troponin
activator
NCT02644668 II Cytokinetics, Astellas
Pharma Global
Development, Inc.
SRK-015 Myostatin
inhibitor
Trial announced Trial
announced
Scholar Rock
EAP expanded access programme, HDAC histone deacetylase, SMA spinal muscular atrophy, SMN survival motor neuron
aReferences in this table are only to published, peer-reviewed studies
Table 2 Summary of the main pharmacological characteristics of current SMA therapies and therapies under development
Drug Administration route Effect on SMN levels Pharmacokinetics Most frequent
adverse events
Spinraza Intrathecal; initial loading doses
(2–4 weeks), repeated
maintenance doses for the
duration of the disease
161% increase (CSF levels, 9-mg dose)
[54], 20–40% increased exon 7 inclusion
across spinal cord levels [53], increased
levels in motor neurons [53]
Mean time to max.
plasma concentration:
1.7–6 h
Mean terminal
elimination half-life:
135–177 days in
CSF, 63–87 in plasma
Lower respiratory
infection, upper
respiratory
infection,
constipation
AVXS-101 One-off intravenous (with
prednisolone,C 30 days)
Not reported Not reported Upper respiratory
tract infection,
vomiting,
constipation
Branaplam
(LMI070)
Oral (weekly) N/A N/A N/A
RG7916 Oral (daily) N/A N/A N/A
Valproic
acid
Oral (2–3 times daily) (with L-
carnitine twice daily)
Unchanged [71–73] Mean overnight trough
levels maintained at
50–65 mg/dL
Weight gain
Olesoxime Oral (daily) – Mean plasma trough
concentration:
4130–16,567 ng/mL
Vomiting, cough,
pyrexia and
nasopharyngitis
CSF cerebrospinal fluid, N/A not available, SMA spinal muscular atrophy
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significant improvement in survival of Spinraza-treated
patients compared to controls [56]. Also, motor function
was improved in Spinraza-treated infants who required
permanent ventilation compared to ventilation-dependent,
sham-controlled infants. The most frequent adverse events
in this study were respiratory infections and constipation
[5, 56]. In a similar phase III clinical trial (CHERISH),
Spinraza was studied in type II and III SMA patients who
presented with clinical symptoms after 6 months of age.
Interim analysis of 126 patients enrolled on the CHERISH
study revealed a significant improvement in motor function
at 15 months from baseline [assessed by the Hammersmith
Functional Motor Scale Expanded (HFMSE)] in Spinraza-
treated patients compared to controls [5, 56, 57]. Here,
adverse events were largely related to the lumbar puncture
procedure (headache, back pain and post-lumbar puncture
syndrome) or were similar to those observed in the
ENDEAR trial [5, 56]. Following favourable interim
analyses of both the ENDEAR and CHERISH studies, the
trials were stopped and the patients were transitioned onto
SHINE, an open-label extension study in which the long-
term efficacy of treatment with Spinraza will be assessed
[56–58].
Alongside these studies, a phase II clinical trial (NUR-
TURE) aims to address the effect of Spinraza treatment on
pre-symptomatic SMA patients. Here, SMN1 deletion car-
riers (with two or three copies of SMN2, SMA type I/II
genotypes) receive Spinraza treatment before 6 weeks of
age, in advance of the onset of overt disease symptoms.
The NURTURE trial is an open-label, single-arm study
comparing pre-symptomatic Spinraza efficacy to a control
group of affected siblings and natural history data [59].
Initial results from the second interim analysis indicate that
motor milestones (such as sitting and crawling) are gen-
erally achieved at age-appropriate time points, indicating a
significantly greater effect of a pre-symptomatic treatment
compared to treatment starting after symptom onset
[5, 59, 60]. Despite this, however, only three of nine
patients were standing unaided following 1 year of treat-
ment [60], indicating that even pre-symptomatic treatment
with Spinraza does not represent a complete ‘cure’ for
SMA.
In summary, these promising initial results have been
greeted with enthusiasm by clinicians, research scientists
and the patient community alike. It will be of great interest
to follow the results from current follow-up trials as they
become available in order to ascertain more about the long-
term efficacy and safety of Spinraza for treatment of SMA.
Moreover, ongoing preclinical studies have revealed that
next-generation oligonucleotides can be developed that
have a therapeutic effect comparable to that of Spinraza,
but which can be delivered through less invasive (e.g.
intravenously) delivery routes and at lower doses [61].
3.1.2 Gene Therapy (AVXS-101)
A more direct approach to increase SMN protein levels is
restoring SMN expression by gene therapy. In preclinical
studies in SMA mouse models, adeno-associated virus
(AAV)-mediated SMN1 gene replacement resulted in
widespread expression of SMN in the spinal cord and
significantly increased survival [39–41, 62]. Further studies
in primates indicated that systemically delivered AAV9-
SMN1 efficiently crossed the blood–brain barrier, resulting
in transgene expression in brain, spinal motor neurons,
dorsal root ganglia neurons and glial cells throughout the
CNS, in addition to widespread expression in the liver,
heart and skeletal muscle [63]. Based on these promising
preclinical studies, a phase I study was initiated to test the
safety and efficacy of SMN1 gene therapy (AVXS-101,
AveXis) using a self-complimentary adeno-associated
virus serotype 9 (scAAV9) delivered as a single dose
intravenously to type I SMA patients (with two copies of
SMN2) (Tables 1 and 2). The first cohort of patients
(n = 3) received the virus at a dose of 6.7 9 1013 vg/kg,
and the second cohort of patients (n = 12) received the
proposed therapeutic dose of 2.0 9 1014 vg/kg [64].
Patients 2–15 also received prednisolone at a daily dose of
1 mg/kg for approximately 30 days, starting 1 day before
viral delivery, to suppress the initial immune response after
delivery of a high viral load [64]. Initial reports of AVXS-
101 treatment indicate an improvement in survival along
with achievement of motor milestones, such as maintaining
head control, sitting unassisted (11 of 12 cohort 2 patients)
and oral feeding (11 of 12 cohort 2 patients) [64].
As a follow-up study, an open-label, single-arm, single-
dose pivotal trial (STR1VE) has been designed to test the
efficacy of AVXS-101 in a minimum of 15 SMA type I
patients (with one or two SMN2 copies) who are symp-
tomatic and less than 6 months old at the time of gene
therapy, across multiple trial centres. Patients will receive
an intravenous infusion of AVXS-101 at a dose of
1.1 9 1014 vg/kg (equivalent to the proposed therapeutic
dose received by cohort 2 in the phase I clinical trial), with
at least a 4-week dosing interval between the first three
participants to review the safety profile of the treatment.
Along with treatment safety, the trial will evaluate the
efficacy as assessed by the achievement of developmental
milestones (sitting for 30 seconds at 18 months) and event-
free survival at 14 months [65]. Future developments are
eagerly awaited, as AVXS-101 provides an opportunity to
substantially improve SMA via one-off virus dosing.
However, although some promising advancements have
recently been made, viral gene therapy approaches are still
not commonplace in the clinic and careful monitoring of
gene therapy-treated patients will be required to assess
long-term safety and durability of the treatment.
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3.1.3 SMN2 Splice-Modifying Small Molecules (RG7916
and LMI070)
In addition to these ASO and gene therapy approaches to
increase SMN levels, more traditional pharmacological,
small molecule-based approaches to target SMN2 splicing
have also been developed. Initial screens in mouse models
of SMA indicate that orally available small molecules can
efficiently increase the production of full-length SMN2
mRNA and SMN protein. These studies demonstrated an
improvement in motor function, protection of the neuro-
muscular system from degeneration and increased survival
in SMA model mice [42]. After these promising preclinical
results, two independently developed drugs are being tested
in phase I and II clinical trials. The first of these drugs,
branaplam (formerly LMI070, Novartis) is based on a
weekly drug dose, and initial studies investigated the safety
and tolerability over a 13-week trial period, with a subse-
quent 13-month extension to continue safety monitoring
and assess efficacy in SMA type I patients with two copies
of SMN2 (Tables 1 and 2). Initial results suggested some
improvements in motor function and indicated adverse
events that were mostly mild and reversible [66]. However,
enrolment onto the trial was temporarily paused because of
the occurrence of nerve injury in a parallel chronic pre-
clinical toxicology study. This problem has now been
addressed, and enrolment on the trial has been resumed
with the implementation of additional nerve tests and the
option of the weekly branaplam dose administrated orally
rather than by feeding tube only [67, 68].
The second small molecule SMN2-splicing modifier in
phase II clinical trials is RG7916 (RO7034067, Roche)
(Tables 1 and 2). In a single ascending dose study in
healthy volunteers, it was shown that RG7916 was safe,
well-tolerated and increased full-length SMN2 mRNA
levels. Following this, several phase II clinical trials have
been initiated in which RG7916 is administered orally on a
daily basis to SMA patients with two or more copies of
SMN2. Two of these trials are two-part trials (FIREFISH
and SUNFISH), in which the first part of the trial assesses
the safety of two dose levels of RG7916 and the second
part aims to investigate the efficacy of the most appropriate
dose [69]. FIREFISH is an open-label trial in which
RG7916 is administered to SMA type I patients aged
between 1 and 7 months old, while the SUNFISH trial
investigates RG7916 in type II and type III SMA patients
aged 2–25 years (ambulatory and non-ambulatory). In
contrast to FIREFISH, SUNFISH is a randomized, double-
blind, placebo-controlled clinical trial. Initial reports of
both FIREFISH and SUNFISH suggest some benefit of the
therapy for SMA patients [69]. Following successful
selection of the appropriate dose, the SUNFISH trial has
now progressed to the pivotal second part of the study on
non-ambulatory type II and III SMA patients [70]. The
final, phase II clinical trial of RG7916 (JEWELFISH) is an
open-label trial investigating safety, tolerability and effi-
cacy in patients previously treated with other SMN2-tar-
geting small molecule therapies [69].
Although the initial results from these trials indicate
modest functional improvement, the oral delivery of these
drugs makes them more flexible and easier and safer to
administer than both CNS-delivered ASOs and viral gene
therapy. Therefore, these drugs, if and when formally
approved, are likely to play a significant role in the clinic in
coming years.
3.1.4 SMN Protein-Enhancing Molecules (Valproic Acid)
Finally, initial studies that preceded the development of
ASOs, gene therapy and small molecule splice enhancers,
aimed to upregulate SMN2 transcription by inhibiting his-
tone deacetylases (HDACs). Of these HDAC inhibitors,
valproic acid (VPA) has been studied in particularly great
detail and is one of the only therapeutic strategies for SMA
with published results from multiple clinical trials
(Tables 1 and 2). Although the consensus now is that VPA
does not provide significant benefits for SMA patients, the
trials that showed this preceded many current studies and
have provided important lessons for current clinical trials.
An initial phase II, open-label trial of VPA in type I, II
and III SMA patients aged 2–31 years indicated that VPA
was safe and well-tolerated [71]. The patients received
VPA in the form of divalproex sodium-coated particles
(125 mg per capsule) in divided doses, two to three times
daily, to maintain overnight trough levels of 50–100 mg/
dL; indeed, at the three treatment assessments (3, 6 and
12 months), mean overnight trough levels were between 50
and 65 mg/dL. This trial identified common adverse events
of weight gain and reductions in total or free plasma car-
nitine, which caused a worsening of gross motor function
in two participants [71]. While there was no significant
change in full-length SMN transcript levels following
treatment with VPA, a significant improvement in motor
function, primarily in patients under 5 years of age, was
observed. Importantly, the primary conclusions of this
study were that subsequent VPA clinical trials should be
conducted on more restricted cohorts of patients (e.g.
patients with the same type of SMA or similar age of onset)
and that carnitine should be given as a supplement to all
subjects [71].
Following this initial phase II trial, several subsequent
trials on defined cohorts of SMA patients were conducted.
The first of these was the two-part CARNI-VAL trial; both
cohorts received VPA at the same dose as the previous
phase II trial as well as L-carnitine supplement (100 mg/
mL liquid) at a dosage of 50 mg/kg/day (maximum of
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1000 mg) divided into two daily doses [72, 73]. CARNI-
VAL part 1 was a double-blind, placebo-controlled, ran-
domized clinical trial on non-ambulatory SMA patients
aged 2–8 years [73], whereas part 2 was an open-label trial
in ambulatory SMA patients aged 3–17 years [72]. A
similar double-blind, placebo-controlled, cross-over clini-
cal trial of VPA (VALIANT; no carnitine supplement) was
performed in ambulatory adults with SMA [74]. In all three
trials, VPA did not improve strength or motor function in
SMA patients compared to baseline or placebo controls;
however, some younger patients on the CARNI-VAL part
1 trial did show improvement in motor function [72–74].
These results were confirmed by an independent trial of
VPA in type II and III SMA patients in which no benefit
was observed in type III SMA patients, but a significant
improvement in motor function in type II SMA patients
was seen [75]. Finally, in another clinical trial, L-carnitine
and VPA were administered to SMA type I patients
between the ages of 2 weeks and 12 months in an open-
label study. Again, there was no impact on motor function
and no improvement in survival in the treated cohort [76].
Interestingly, a cellular mechanism that might be related
to these disappointing results has since been identified. In a
study investigating the responsiveness to VPA in SMA
patients, it was found that only one-third of SMA patients
treated with VPA responded to treatment and had increased
SMN2 transcript levels [77]. Transcriptome-wide profiling
of SMA fibroblasts identified that CD36 RNA expression
was fivefold higher in non-responders compared to VPA-
responders, and indeed, subsequent analysis revealed that
CD36 overexpression prevented VPA-induced SMN
expression [77]. This finding makes it potentially inter-
esting to speculate about the usefulness of VPA for SMA
patients who are ineligible for SMN-targeted therapies but
have low levels of CD36. Despite the lack of positive
outcomes in VPA clinical trials, being early SMA clinical
trials, they provided valuable insights into how to structure
clinical trials in SMA cohorts. One of the key outcomes of
the initial phase II VPA trial was that clinical trials should
be conducted on restricted cohorts of SMA patients [71],
something that has been accepted for more recent SMA
clinical trials. Furthermore, VPA trials in restricted cohorts
of SMA patients identified a range of feasible and reliable
outcome measures for different populations of SMA
patients that can be readily used in future clinical trials
[72–74, 76]. Moreover, these clinical trials also highlighted
pitfalls of current clinical trial design. For example, SMN
protein and transcript levels were measured in peripheral
blood, where no difference was detected [71–73]. How-
ever, blood SMN expression levels might differ from those
measured in the CNS and therefore might not completely
reflect expression changes in more disease-affected tissues.
Finally, from these analyses, the benefits of VPA were only
evident in young SMA type II patients [73, 75], suggesting
that early treatment will be necessary to prevent effects of
SMN deficiency on motor function and that if treating older
or ambulatory SMA patients, a longer course of treatment
may be necessary to reverse the disease process.
3.2 SMN-Independent Therapies
3.2.1 Neuroprotection (Olesoxime)
While the first-generation of SMN-targeting therapies
progress through the various phases of clinical research,
several second-generation, SMN-independent therapies are
already under clinical development. These second-genera-
tion therapies are initially centred around administering
neuroprotective factors or enhancing muscle strength.
Olesoxime (Hoffman-La Roche/Trophos SA) is a neuro-
protective factor which exerts its neuroprotective effects by
binding to components of the mitochondrial permeability
pore, thereby preventing excessive permeability under
stress conditions [78–81] (Tables 1 and 2). In animal
models of neurodegeneration, olesoxime has shown neu-
roprotective effects by preventing release of pro-apoptotic
factors from mitochondria and maintaining energy pro-
duction [78, 81]. The efficacy of olesoxime was assessed in
a randomized, double-blind, placebo-controlled phase II
clinical trial for type II and non-ambulatory type III SMA
patients aged 3–25 years [82]. Olesoxime was adminis-
tered daily at a dose of 10 mg/kg in an oral liquid sus-
pension (100 mg/mL) for a trial duration of 24 months.
The average individual plasma trough concentration of
olesoxime (Cavg) was 8590 ng/mL, with a range of
4130–16,567 ng/mL. The dose of olesoxime was safe for
the duration of the study, with an adverse event profile
similar to the placebo; the most common adverse events in
the treatment group were vomiting, cough, pyrexia and
nasopharyngitis. The outcomes of this clinical trial suggest
that olesoxime supported the maintenance of motor func-
tion, particularly in a subgroup of patients aged 6–15 years
and in patients who had high exposure to olesoxime (de-
fined as CavgC 7500 ng/mL) [82]. An open-label, single-
arm study is currently ongoing to evaluate long-term
safety, efficacy and tolerability of olesoxime in patients
previously enrolled on the phase II study. As olesoxime is a
general neuroprotective agent, the outcomes of these
studies are potentially of interest for the treatment of other
neurodegenerative diseases.
3.2.2 Muscle-Enhancing Drugs (CK-107 and SRK-015)
Another group of therapies currently in development for
the treatment of SMA is aimed at improving neuromus-
cular function, muscular weakness and muscle fatigue. CK-
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107 (formerly CK-2127107, Cytokinetics) is a troponin
complex activator that slows calcium release from fast
skeletal muscle troponin to sensitize the sarcomere to
calcium, leading to an increased force output at submaxi-
mal frequencies of motor nerve stimulation (Table 1).
Indeed, preclinical studies indicated that CK-107 reduces
fatigability of rat skeletal muscle in vivo [83]. Following
promising preclinical and safety phase I pharmacokinetic
and pharmacodynamic profiles in healthy volunteers, CK-
107 is currently in phase II clinical trials. In this double-
blind, randomized, placebo-controlled clinical trial, type II,
III and IV SMA patients aged 12 years and older will
receive 150 mg CK-107 (or placebo) twice daily for
8 weeks in cohort 1. Following analysis of safety and
pharmacokinetics, a dose of up to 450 mg CK-107 will be
administered twice daily to cohort 2 [84]. The outcome of
this trial is expected in the near future.
In addition, the myostatin inhibitor SRK-015 (Scholar
Rock) has been shown to increase muscle mass and force in
healthy mice (Table 1). SRK-015 acts by binding to latent
myostatin and hindering protease cleavage which is
thought to prevent latent myostatin activation, leading to
increased muscle cell growth and differentiation [85]. After
preclinical studies showed that SRK-015 improved muscle
function in SMA mice, it was announced that SRK-015 is
due to enter clinical trials for SMA in 2018 as both a
standalone therapy and in combination with SMN-targeted
therapies [86]. However, due to dysregulation of compo-
nents of the myostatin signalling pathway in SMA [87], the
therapeutic effect of SRK-015 may be limited. Although
the efficacy of neuroprotective and muscle-enhancing
drugs remains to be determined, positive results in these
trials will provide interesting opportunities to enhance the
efficacy of SMN-targeted trials.
4 Future Directions for SMA Therapy
Development
4.1 Combination of SMN-Targeted
and Neuroprotective Approaches
The approval of Spinraza, alongside other ongoing clinical
trials, holds great promise for the treatment of SMA over
the coming years. However, when considering results from
preclinical studies and initial results from clinical trials, it
is likely that SMN-targeted therapy on its own will not be
sufficient to halt or restore all disease-associated pheno-
types [43, 50, 88]. One major line of research attempts to
directly address these issues by exploring the possibility of
developing combinatorial therapeutic approaches. These
approaches aim to combine SMN-targeted therapies with
additional, SMN-independent strategies. Indeed, the
recently announced trial for myostatin inhibitor SRK-015
will consist of groups of patients that both have or have not
concurrently received Spinraza. Of interest, several recent
preclinical studies have used innovative approaches to
study the effect of combining SMN-targeted therapies with
further preclinical targets. In these studies, mouse models
of SMA were treated with suboptimal doses of Spinraza, or
comparable ASOs, to generate intermediate models of
SMA [13, 89]. In intermediate models, a partial rescue of
the disease phenotype by ASO treatment is thought to
better represent the clinical improvements being observed
in patients enrolled in clinical trials for Spinraza [88].
Targeting of known modifiers of human disease subse-
quently leads to an improvement in disease progression
that is vastly better than when SMN is targeted alone. For
example, studies in discordant SMA families have previ-
ously identified PLS3 as a potent modifier of SMA
pathology: SMN1 deletion carriers were completely pro-
tected from developing SMA by high expression levels of
PLS3 [14]. When increasing PLS3 levels in intermediate
mouse models of SMA, either by gene therapy approaches
or genetically, survival and overall phenotype vastly
improved [13, 89]. Similarly, depletion of NCALD,
another modifier of SMA in discordant families, vastly
improved SMA-associated phenotypes in a number of
animal models, including an intermediate mouse model
[15]. Functionally, these proteins are linked to actin
dynamics and endocytosis, suggesting an important role for
these pathways in SMA pathogenesis. These findings fur-
ther illustrate the need to develop therapies that go beyond
SMN targeting and build on the basic understanding of
disease pathogenesis to optimize therapy development
(Fig. 1).
4.2 Promising Preclinical Leads
For the development of agents that show promise for
combinatorial approaches, it is of interest to note that many
disease-modifying molecular pathways have been discov-
ered in SMA. Targeting each of these pathways holds
potential promise for further therapy development in SMA.
For example, gene therapy approaches that restore UBA1
expression levels have been shown to lead to broad
improvement of pathology and a modest increase in sur-
vival in an SMA mouse model, independent of SMN tar-
geting [27]. Similarly, the compound ML372, which
selectively inhibits the ubiquitylation of SMN, has been
shown to increase SMN protein levels and improve sur-
vival and motor function of SMA mice [90]. Also, treat-
ment with the beta-catenin inhibitor quercetin, a plant
extract that is widely available as a food supplement, sig-
nificantly improves neuromuscular function in animal
models of SMA [28]. In addition, other preclinical work
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has also identified fasudil and Y-27632 as promising
therapeutic leads for SMA. In these studies, inhibition of
the RhoA/Rho kinase (ROCK) pathway was shown to
improve the phenotype in mouse models of SMA by par-
tially restoring actin dynamics that lead to improved
function at the neuromuscular junction [91, 92]. Finally,
recent work has identified changes in ribosome biology as
an important cellular pathway that might be associated with
motor neuron-specific degeneration in SMA [31]. Consid-
ering the central role of local protein translation in main-
taining neuronal homeostasis these findings warrant further
investigation of these pathways, including how they can be
effectively therapeutically targeted.
Discussing all proteins and pathways that have been
shown to modulate SMA phenotypes in detail would go
beyond the scope of this review. However, the above
examples aim to illustrate that recent basic research into
disease mechanisms of SMA has not stopped at the level of
understanding SMN function and replacing SMN expres-
sion, and is likely to lead to further insights in disease
pathogenesis, including the identification of novel thera-
peutic targets.
4.3 Further Considerations
Despite the positivity and promise that surround the current
developments in the SMA field, several factors complicate
further research into current and novel therapies for SMA
[93]. First, basic research indicates that the timing of SMN-
targeted therapies is essential for maximum efficacy, which
is confirmed by initial trial results [5, 43, 53]. Delays in
diagnosis might not always make quick therapeutic inter-
vention possible, particularly in milder cases of the disease,
which calls for the development of further, SMN-inde-
pendent therapies. Moreover, strategies such as neonatal
screening should be discussed to minimize diagnostic delay
[94, 95]. Second, despite a shared genetic basis, clinical
heterogeneity between patients exists. Indeed, although
Spinraza has been approved for the treatment of all types of
SMA, data on the efficacy of Spinraza in type III and IV
SMA are still relatively sparse. Finding therapies that are
efficient across SMA clinical phenotypes will be a complex
challenge, and results, particularly for milder forms of the
disease, are likely to take a long time to establish. Fur-
thermore, it is to be expected that future trial design will be
complex, as the effect of Spinraza on the clinical progress
of SMA is still incompletely understood and yet, many
patients are likely to begin treatment soon. Comparing the
efficacy of Spinraza to other SMN-targeted therapies will
be challenging, as delivery routes can be complex and
washout periods can be long. Indeed, the design of future
studies investigating the efficacy of combinatorial therapies
will be even more challenging, as many patients will likely
have already received one or more SMN-targeting drug. In
addition to the practical issues around study design and
patient selection, a number of ethical and financial issues
Fig. 1 Overview of potential combinatorial approaches for SMA
therapy. Most therapies currently under development for the treatment
for SMA work by targeting SMN levels. Additional approaches being
explored include drugs designed to enhance muscle function. Other
therapies, including olesoxime and several alternative promising
preclinical leads, support the neuromuscular system (and potentially
other non-neuronal cells and tissues) by targeting a number of cellular
pathways, such as the mitochondrion (olesoxime), actin dynamics
(PLS3, fasudil and Y-27632), endocytosis (NCALD) and/or ubiquitin
homeostasis (UBA1, ML372). Combinations of these various
approaches will likely be required to provide robust rescue of all
SMA-associated pathologies across a patient’s lifespan. NCALD
neurocalcin delta, PLS3 plastin-3, SMA spinal muscular atrophy, SMN
survival motor neuron, UBA1 ubiquitin-like modifier activating
enzyme 1
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are now becoming increasingly relevant. For example, the
pricing of Spinraza might prevent some groups of patients
from gaining access to treatment. Moreover, although
drugs like Spinraza and AVXS-101 lead to increased sur-
vival, little is known as yet about the quality of life as
perceived by the treated patients and their families. Each of
these issues will require consideration for the successful
further development of therapies aiming to provide robust,
life-long treatments for SMA.
5 Concluding Remarks
The recent approval of Spinraza is a milestone develop-
ment for the SMA research and patient communities. The
significance of the availability of an approved, disease-
modifying therapy for the treatment of a monogenetic
motor neuron disease for future research, both basic and
clinical, cannot be understated. Developments in the SMA
field will no doubt be very carefully monitored by sci-
entists and clinicians studying related disorders and are
likely to provide important lessons for the study of other
monogenetic, neurological diseases and motor neuron
diseases. Increasing our understanding of the long-term
efficacy of Spinraza, including that in type III and IV
SMA patients, and that of other drugs that are currently in
development for SMA will be of great interest in the
years to come and provide further hope to SMA patients
and their families for efficient treatment of this devas-
tating disorder.
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